| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cefamandole Nafate, like other β-lactam antibiotics, exerts its antibacterial activity by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidase activity of PBPs, preventing the cross-linking of peptidoglycan chains, which is essential for bacterial cell wall integrity. This leads to cell lysis and bacterial death.
|
|---|---|
| ln Vitro |
In bacteriological media, cefamandole sodium is quickly changed to cefamandole, which has a half-life of less than an hour at pH 7.0 or higher. Nevertheless, in log-phase inhibition tests, cefamandole was more stable at pH 6.0, and the interaction between cefamandole and cefamendol could be explained [2].
Cefamandole Nafate is a second-generation broad-spectrum cephalosporin antibiotic. It inhibits the growth of E. cloacae. Its activity against Gram-positive bacteria is similar to cephalothin, and it is sensitive to Gram-negative bacteria including Escherichia coli, Pneumococci, Proteus, and influenzae. Its in vitro activity is consistent with its mechanism of inhibiting bacterial cell wall synthesis. |
| ln Vivo |
Rats were given intravenous cefamandole sodium at dosages ranging from 250 to 1,000 mg/kg five days a week for a month in order to assess its toxicity [1]. After one month of cefamandole sodium administration, there were no treatment-related side effects on growth, food consumption, clinical chemistry, hematology, or organ weights [1].
Cefamandole Nafate is a prodrug which is administered parenterally. It is used to study the effects of expression and inhibition of PBP 2A. It is no longer available in the United States. Its in vivo efficacy is established through its clinical use. |
| Enzyme Assay |
Cefamandole Nafate's antibacterial activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs), particularly PBP 2A, can be evaluated using competitive binding assays.
|
| Cell Assay |
Cellular assays for cefamandole Nafate are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units.
|
| Animal Protocol |
In vivo animal model protocols for cefamandole Nafate would involve its parenteral administration to animal models of infection to evaluate its efficacy. Studies may include models of respiratory, urinary, and biliary tract infections.
|
| ADME/Pharmacokinetics |
Cefamandole Nafate has a molecular weight of 512.49 and a molecular formula of C19H17N6NaO6S2. It is administered parenterally. Specific pharmacokinetic data is not extensively detailed in the available literature.
|
| Toxicity/Toxicokinetics |
Cefamandole Nafate is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site.
|
| References | |
| Additional Infomation |
Cefamandole sodium is a cephalosporin prodrug with (R)-O-formylmandelic acid and N-methylthiotetrazole side groups. It can be used as both a prodrug and an antibacterial agent. Its molecular structure contains an O-formylcefamandole (1-) group. Cefamandole sodium is the sodium salt of cefamandole formyl ester. Cefamandole sodium is a prodrug that, upon hydrolysis by plasma esterases, yields cefamandole, a semi-synthetic β-lactam second-generation cephalosporin antibiotic with bactericidal activity. Cefamandole binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of bacterial cell walls. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall, resulting in cell lysis.
Cefamandole Nafate (CAS# 42540-40-9) is a second-generation broad-spectrum cephalosporin antibiotic administered parenterally. It is the formate ester prodrug form of cefamandole. It is no longer available in the United States. |
| Molecular Formula |
C19H17N6NAO6S2
|
|---|---|
| Molecular Weight |
512.49
|
| Exact Mass |
512.054
|
| CAS # |
42540-40-9
|
| Related CAS # |
Cefamandole sodium;30034-03-8;Cefamandole;34444-01-4
|
| PubChem CID |
23665731
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
190-193ºC
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
844
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)OC=O)SC2)C(=O)[O-].[Na+]
|
| InChi Key |
ICZOIXFFVKYXOM-YCLOEFEOSA-M
|
| InChi Code |
InChI=1S/C19H18N6O6S2.Na/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10;/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30);/q;+1/p-1/t12-,14-,17-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
Cemandil sodium salt; Cephamandole nafate; Cefamandole Nafate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~175 mg/mL (~341.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. View More
Solubility in Formulation 4: 100 mg/mL (195.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), Clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9513 mL | 9.7563 mL | 19.5126 mL | |
| 5 mM | 0.3903 mL | 1.9513 mL | 3.9025 mL | |
| 10 mM | 0.1951 mL | 0.9756 mL | 1.9513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
